



Aduro Biotech to Present at NASDAQ Investor Conference

November 27, 2015

BERKELEY, Calif., Nov. 27, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 33rd NASDAQ Investor Conference in London, UK on Tuesday, December 1, 2015, at 8:00 am Greenwich Mean Time.

To access the live webcast and subsequent archived recording of this and the company's other presentations, please visit Aduro's website at www.aduro.com.

About Aduro

Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of *Listeria* that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro's B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.

Contact:

Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264

Media Contact:

Angela Bitting
925 202 6211
press@aduro.com



Aduro Biotech, Inc.